Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Crow's Feet Lines in Japan
NCT01797081Phase 3Completed
- Sponsor
- Allergan
- Start
- Jan 2013
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of onabotulinumtoxinA in periorbital wrinkles (4 arms), sponsored by Allergan. Primary endpoint: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A) at Day 30. Started Jan 2013; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
periorbital wrinkles
Beyond the preview
Go deeper on NCT01797081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01797081.